Leqembi, an Alzheimer's drug, offers hope for patients like Missie Meeks, diagnosed with early-stage Alzheimer's. Approved in July 2023, it helps slow cognitive decline, allowing for a more normal life. However, challenges in access and concerns about its effectiveness remain.